Neurogene, Inc. (NGNE)
24.21
+0.28
(+1.17%)
USD |
NASDAQ |
Nov 16, 10:44
Neurogene EPS Diluted (Quarterly) : -1.048 for Sept. 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -1.048 |
| June 30, 2026 | -1.529 |
| March 31, 2026 | -1.387 |
| December 31, 2025 | -1.597 |
| September 30, 2025 | -0.9898 |
| June 30, 2025 | -1.046 |
| March 31, 2025 | -1.079 |
| December 31, 2024 | -1.314 |
| September 30, 2024 | -1.192 |
| June 30, 2024 | -1.092 |
| March 31, 2024 | -1.001 |
| December 31, 2023 | -1.209 |
| September 30, 2023 | -8.166 |
| June 30, 2023 | -0.0371 |
| March 31, 2023 | -7.070 |
| December 31, 2022 | -1.048 |
| September 30, 2022 | -0.2366 |
| June 30, 2022 | -0.2842 |
| March 31, 2022 | -0.2784 |
| December 31, 2021 | -0.3572 |
| September 30, 2021 | -0.2804 |
| June 30, 2021 | -0.2749 |
| March 31, 2021 | -0.2721 |
| December 31, 2020 | -0.2995 |
| September 30, 2020 | -0.0415 |
| Date | Value |
|---|---|
| June 30, 2020 | -0.1973 |
| March 31, 2020 | -0.1758 |
| December 31, 2019 | -0.23 |
| September 30, 2019 | -2.258 |
| June 30, 2019 | 0.00 |
| March 31, 2019 | -0.0938 |
| December 31, 2018 | -0.2076 |
| September 30, 2018 | -0.637 |
| June 30, 2018 | 0.12 |
| March 31, 2018 | -0.62 |
| December 31, 2017 | -0.69 |
| September 30, 2017 | -0.50 |
| June 30, 2017 | -0.59 |
| March 31, 2017 | -0.36 |
| December 31, 2016 | -0.48 |
| September 30, 2016 | -0.46 |
| June 30, 2016 | -0.63 |
| March 31, 2016 | -0.39 |
| December 31, 2015 | -0.33 |
| September 30, 2015 | -0.43 |
| June 30, 2015 | -0.44 |
| March 31, 2015 | -0.60 |
| December 31, 2014 | -0.76 |
| September 30, 2014 | -0.59 |
| June 30, 2014 | -0.51 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 0.305 |
| Alnylam Pharmaceuticals, Inc. | 15.72 |
| Anika Therapeutics, Inc. | -0.0232 |
| Savara, Inc. | -0.1691 |
| Arrowhead Pharmaceuticals, Inc. | -3.029 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -29.02M |
| Total Expenses (Quarterly) | 29.02M |
| Enterprise Value | 143.03M |
| Earnings Yield | -22.97% |
| Normalized Earnings Yield | -22.97 |